Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex
Innovatus Capital partners joins as a new investor; Scott Hutton joins as COO
Biodesix and Professor Fred R. Hirsch announced a collaboration on a PD-L1 study
Media Advisory: Dr. Heinrich Roder, Biodesix CTO, to speak at precision medicine world conference
Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.
Biodesix leaders shared commercial and pipeline updates at the annual qPCR and dPCR Congress
Biodesix announces new data, presented at AMP2017, supporting the analytic validity of automated RNA extraction with the GeneStrat test
Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients
Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC
Biodesix will present posters and an oral presentation of data at SITC 2017 Annual Meeting.